Live news related to MAAT PHARMA stock (FR0012634822): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on MAAT PHARMA mainly cover M&A activity et share price moves. The stock trades at €2,76 on Euronext Paris at the last update. This page lists the articles published on MAAT PHARMA stock to track the share price, company announcements and any item likely to influence market perception.
The stock of the Lyon-based biotech company plunges during the session, after a brief rebound on Friday. The stock is now trading at its lowest, as th…
However, the stock remains significantly distant from its pre-CHMP adverse signal levels, and the formal vote of the European committee remains the ce…
MaaT Pharma's stock experiences a sharp decline this Thursday midday, with the share price of the Lyon-based biotech falling to €2.97. The drop comes …
Lyon-based biotech company MaaT Pharma has been informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
The stock of the Lyon-based biotech company recorded one of its strongest daily gains in several months, reaching 6.02 euros. This rebound follows a s…
MaaT Pharma announces the publication of the CHRONOS study, a multicenter retrospective analysis evaluating third-line treatments in 59 patients with …
MaaT Pharma releases its annual results for 2025 and updates on its microbiome therapy portfolio. The year 2026 is set to be pivotal with the ongoing …
MaaT Pharma announced on Monday the presentation of the final results of the pivotal ARES trial evaluating MaaT013 in acute gastrointestinal graft-ver…
MaaT Pharma announces the presentation of clinical data related to its therapeutic portfolio at the 2026 Annual EBMT Congress, to be held from March 2…
MaaT Pharma's stock increases by 3.2% this Thursday morning to 7.10 euros, after closing at 6.88 euros the previous day. This rebound occurs in a cont…
